Legal & General Group Plc Has $6.43 Million Stock Position in Inspire Medical Systems, Inc. $INSP

Legal & General Group Plc trimmed its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSPFree Report) by 17.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,756 shares of the company’s stock after selling 14,524 shares during the period. Legal & General Group Plc owned approximately 0.24% of Inspire Medical Systems worth $6,434,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of INSP. CWM LLC raised its position in Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after buying an additional 242 shares during the period. V Square Quantitative Management LLC acquired a new position in Inspire Medical Systems in the 4th quarter worth about $40,000. Larson Financial Group LLC increased its position in Inspire Medical Systems by 21,266.7% in the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after purchasing an additional 638 shares during the last quarter. Daiwa Securities Group Inc. increased its position in Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after purchasing an additional 130 shares during the last quarter. Finally, Hantz Financial Services Inc. increased its position in Inspire Medical Systems by 194.0% in the 4th quarter. Hantz Financial Services Inc. now owns 685 shares of the company’s stock worth $63,000 after purchasing an additional 452 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP opened at $41.29 on Friday. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 9.20, a P/E/G ratio of 4.25 and a beta of 0.73. The business’s 50-day simple moving average is $48.93 and its 200-day simple moving average is $73.29. Inspire Medical Systems, Inc. has a 52 week low of $38.91 and a 52 week high of $147.03.

Inspire Medical Systems (NYSE:INSPGet Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The business had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities research analysts forecast that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on INSP. JPMorgan Chase & Co. dropped their target price on Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Morgan Stanley set a $60.00 target price on Inspire Medical Systems in a research report on Wednesday, February 18th. Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a research report on Friday, May 22nd. Robert W. Baird dropped their target price on Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Finally, Wolfe Research lowered Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a research report on Friday, February 13th. Four research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Inspire Medical Systems presently has a consensus rating of “Hold” and a consensus target price of $81.84.

Get Our Latest Stock Analysis on INSP

Inspire Medical Systems Company Profile

(Free Report)

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

See Also

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSPFree Report).

Institutional Ownership by Quarter for Inspire Medical Systems (NYSE:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.